<b>Background/Objectives</b>: Signaling imbalances involving epidermal growth factor receptor (EGFR) and aldose reductase (ALR2) are frequently associated with the biology of several solid tumors, including non-small-cell lung cancer (NSCLC) and breast cancer. Here, EGFR is linked to non-small cell lung carcinoma.